ADAR1 Capital Management’s Pasithea Therapeutics KTTA Stock Holding History

ADAR1 Capital Management’s Portfolio KTTA Stock Details KTTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-27,696	Closed	-$140K	–	315
2024 Q2	$140K	Hold	27,696	–	–	0.03%	158
2024 Q1	$201K	Buy	+27,696	New	+$197K	0.05%	120

Other funds holding KTTA

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

ADAR1 Capital Management's KTTA Position: Q3 2024 in Review

ADAR1 Capital Management sold out of Pasithea Therapeutics (KTTA) in Q3 2024, closing a stake of 27,696 shares — an estimated $140K sold.

ADAR1 Capital Management first reported a position in KTTA in Q1 2024 and held it in 2 quarters. The position peaked at $201K in Q1 2024. 6 funds tracked by Wall St. Rank hold KTTA as of Q3 2024.

ADAR1 Capital Management reported no remaining Pasithea Therapeutics position as of Q3 2024 after selling out during the quarter.
ADAR1 Capital Management sold 27,696 Pasithea Therapeutics shares in Q3 2024, an estimated $140K.
ADAR1 Capital Management first reported a position in Pasithea Therapeutics in Q1 2024 and held it in 2 quarters.
ADAR1 Capital Management's Pasithea Therapeutics position peaked at $201K in Q1 2024.
6 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q3 2024.

Based on ADAR1 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.